Novo Nordisk Stages a Two-Front Offensive: Oral Wegovy Explodes in the US While China Beckons
Shares of Novo Nordisk surged more than 4% on Friday to 39.23 euros, as investors digested a barrage…
Novo Nordisk Faces a Two-Front Assault as CVS Drops Wegovy Exclusivity and Brazil Approves a Cheaper
CVS Caremark ends Wegovy’s exclusivity; Brazil approves Ozempic copycat. Novo faces mounting competition in US and emerging markets,…
Novo Nordisk’s Two-Front Data Blitz: Oral Wegovy Scores in Weight Loss as MASH Findings Bolster th
Novo Nordisk’s oral semaglutide shows 21.6% weight loss in early responders, but stock remains 45% off highs amid…
Teen Pill Success Meets Canadian Generic Shock
Novo Nordisk celebrates positive trial results for oral semaglutide in teens while facing first generic Ozempic competition in…